Xenetic Biosciences Inc. (XBIO) 0.2100 $XBIO
Xenetic Biosciences Announces Board Change
GlobeNewswire - Tue Apr 21, 5:05PM CDT
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces the resignation of Chairman Mark Leuchtenberger.
Xenetic Biosciences to Hold Business Update Conference Call January 20th
Business Wire - Fri Jan 16, 4:58PM CST
Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, will hold a conference call on Tuesday, January 20, at 12:00 UK time, 7:00 a.m. ET. M. Scott Maguire, chief executive officer, and Colin Hill, chief financial officer and board member, will provide a business update and answer questions.
Xenetic Biosciences Completes Enrollment of Second Cohort in Phase 2a Study with ErepoXen(R) for Anemia; Hemoglobin Levels Rise into Therapeutic Range over Time
Business Wire - Fri Dec 19, 6:30AM CST
--Compound uses Patented PolyXen(R) Technology for a "Biobetter" Recombinant Erythropoietin
Xenetic Biosciences CEO Delivers "2014 - The Year in Review" Update to Investors and Stakeholders
Business Wire - Thu Dec 18, 8:40AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that CEO M. Scott Maguire has written a Letter to Shareholders, the full text of which appears below:
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.03), PFNX: 13.70 (+0.60), INO: 7.97 (-0.02), CMRX: 40.15 (+0.31), RPTP: 11.31 (-0.02), IBIO: 0.89 (+0.04), ANAC: 62.37 (-1.71), PFE: 33.99 (+0.05), GNCA: 9.39 (-0.07), GSK: 44.77 (-0.22), AZN: 69.29 (-0.81), NVS: 103.75 (-0.15)
Xenetic Biosciences Announces OncoHist(TM) Preclinical Data to be Featured in a Poster Presentation at the American Society of Hematology Annual Meeting
Business Wire - Thu Dec 04, 6:30AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that the mechanism of action of OncoHist(TM) in acute myeloid leukemia (AML) will be the subject of a poster presentation at the American Society of Hematology (ASH) 56th ASH Annual Meeting & Exposition. The meeting is being held December 6-9, 2014 in San Francisco and the poster presentation will be from 6:00 p.m. to-8:00 p.m. local time on December 8. The abstract, available here, also will be published in Blood on December 5.
Xenetic Biosciences Partner Completes Dosing of Second Cohort in Phase 2a Study of ErepoXen(R) in Patients with Chronic Kidney Disease on Dialysis
Business Wire - Tue Dec 02, 6:30AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that its license partner and shareholder Serum Institute of India Limited (SIIL) has completed dosing the 10 patients comprising the second cohort of its Phase 2a study with ErepoXen(R), a polysialylated form of erythropoietin (EPO).
Xenetic Biosciences Provides Update on Substantial Patent Grants and Allowances in U.S. and Worldwide
Business Wire - Tue Nov 25, 8:04AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today provided an update on recent patent grants and allowances worldwide.
Xenetic Biosciences Partner Completes First Patient Cohort in Phase 2 Study with MyeloXen(TM) for Multiple Sclerosis
Business Wire - Fri Nov 21, 8:08AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that its license partner Pharmsynthez has completed dosing in patients in its Phase 2 clinical study with MyeloXen(TM) in patients with relapsing remitting and secondary progressive (RRSP) multiple sclerosis (MS).
Xenetic Biosciences to Hold Business Update Conference Call September 23 at 6:00 a.m. Eastern Time
Business Wire - Mon Sep 22, 12:44PM CDT
Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced that it will hold a business update conference call on Tuesday, September 23, 2014 at 11:00 a.m. GMT (6:00 a.m. EDT). M. Scott Maguire, chief executive officer, and Colin Hill, U.K. chief financial officer and board member, will provide a business update and answer questions.
Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R)
Marketwire - Mon Aug 11, 9:27AM CDT
Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces results from its ongoing data analysis of its Phase 2 ErepoXen(R) clinical trial being conducted in Australia and New Zealand.
Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial of ErepoXen(R)
GlobeNewswire - Mon Jun 30, 6:00AM CDT
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced results from its ongoing data analysis of the first cohort of its Phase 2, sequential multiple dose study evaluating the safety and efficacy of ErepoXen, subcutaneously administered polysialylated erythropoietin (PSA-EPO), for the treatment of anemia in Chronic Kidney Disease (CKD) patients who are neither on dialysis nor receiving erythropoiesis stimulating agents. ErepoXen was found safe and well tolerated to date, with no serious adverse events. This is the first data on repeat dosing of PSA-EPO in human subjects demonstrating its tolerability and safety in Western clinical trials. On this basis, the Safety Review Committee authorized a dose increase for the second cohort of the study, which is currently underway and demonstrating early signs of clinical efficacy. The Safety Review Committee intends to meet again in August 2014, and the Company expects additional results to be available in the third quarter of 2014.
Xenetic Biosciences Announces Board Change
GlobeNewswire - Tue Apr 21, 5:05PM CDT
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces the resignation of Chairman Mark Leuchtenberger.
Xenetic Biosciences to Hold Business Update Conference Call January 20th
Business Wire - Fri Jan 16, 4:58PM CST
Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, will hold a conference call on Tuesday, January 20, at 12:00 UK time, 7:00 a.m. ET. M. Scott Maguire, chief executive officer, and Colin Hill, chief financial officer and board member, will provide a business update and answer questions.
Xenetic Biosciences Completes Enrollment of Second Cohort in Phase 2a Study with ErepoXen(R) for Anemia; Hemoglobin Levels Rise into Therapeutic Range over Time
Business Wire - Fri Dec 19, 6:30AM CST
--Compound uses Patented PolyXen(R) Technology for a "Biobetter" Recombinant Erythropoietin
Xenetic Biosciences CEO Delivers "2014 - The Year in Review" Update to Investors and Stakeholders
Business Wire - Thu Dec 18, 8:40AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that CEO M. Scott Maguire has written a Letter to Shareholders, the full text of which appears below:
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.03), PFNX: 13.70 (+0.60), INO: 7.97 (-0.02), CMRX: 40.15 (+0.31), RPTP: 11.31 (-0.02), IBIO: 0.89 (+0.04), ANAC: 62.37 (-1.71), PFE: 33.99 (+0.05), GNCA: 9.39 (-0.07), GSK: 44.77 (-0.22), AZN: 69.29 (-0.81), NVS: 103.75 (-0.15)
Xenetic Biosciences Announces OncoHist(TM) Preclinical Data to be Featured in a Poster Presentation at the American Society of Hematology Annual Meeting
Business Wire - Thu Dec 04, 6:30AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that the mechanism of action of OncoHist(TM) in acute myeloid leukemia (AML) will be the subject of a poster presentation at the American Society of Hematology (ASH) 56th ASH Annual Meeting & Exposition. The meeting is being held December 6-9, 2014 in San Francisco and the poster presentation will be from 6:00 p.m. to-8:00 p.m. local time on December 8. The abstract, available here, also will be published in Blood on December 5.
Xenetic Biosciences Partner Completes Dosing of Second Cohort in Phase 2a Study of ErepoXen(R) in Patients with Chronic Kidney Disease on Dialysis
Business Wire - Tue Dec 02, 6:30AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that its license partner and shareholder Serum Institute of India Limited (SIIL) has completed dosing the 10 patients comprising the second cohort of its Phase 2a study with ErepoXen(R), a polysialylated form of erythropoietin (EPO).
Xenetic Biosciences Provides Update on Substantial Patent Grants and Allowances in U.S. and Worldwide
Business Wire - Tue Nov 25, 8:04AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today provided an update on recent patent grants and allowances worldwide.
Xenetic Biosciences Partner Completes First Patient Cohort in Phase 2 Study with MyeloXen(TM) for Multiple Sclerosis
Business Wire - Fri Nov 21, 8:08AM CST
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that its license partner Pharmsynthez has completed dosing in patients in its Phase 2 clinical study with MyeloXen(TM) in patients with relapsing remitting and secondary progressive (RRSP) multiple sclerosis (MS).
Xenetic Biosciences to Hold Business Update Conference Call September 23 at 6:00 a.m. Eastern Time
Business Wire - Mon Sep 22, 12:44PM CDT
Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced that it will hold a business update conference call on Tuesday, September 23, 2014 at 11:00 a.m. GMT (6:00 a.m. EDT). M. Scott Maguire, chief executive officer, and Colin Hill, U.K. chief financial officer and board member, will provide a business update and answer questions.
Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R)
Marketwire - Mon Aug 11, 9:27AM CDT
Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces results from its ongoing data analysis of its Phase 2 ErepoXen(R) clinical trial being conducted in Australia and New Zealand.
Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial of ErepoXen(R)
GlobeNewswire - Mon Jun 30, 6:00AM CDT
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced results from its ongoing data analysis of the first cohort of its Phase 2, sequential multiple dose study evaluating the safety and efficacy of ErepoXen, subcutaneously administered polysialylated erythropoietin (PSA-EPO), for the treatment of anemia in Chronic Kidney Disease (CKD) patients who are neither on dialysis nor receiving erythropoiesis stimulating agents. ErepoXen was found safe and well tolerated to date, with no serious adverse events. This is the first data on repeat dosing of PSA-EPO in human subjects demonstrating its tolerability and safety in Western clinical trials. On this basis, the Safety Review Committee authorized a dose increase for the second cohort of the study, which is currently underway and demonstrating early signs of clinical efficacy. The Safety Review Committee intends to meet again in August 2014, and the Company expects additional results to be available in the third quarter of 2014.
